Abstract

The premenstrual syndrome (PMS) consists of a set of emotional, behavioural and physical symptoms that recur regularly during the second half of each menstrual cycle, with complete absence of symptoms immediately after menstruation. The intensity of symptoms, rather than their type, usually determines whether the woman seeks treatment. Thirteen years ago we concluded that no firm advice could be given about the drug management of PMS.¹ Has the situation changed?